Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells

Summary: Lenalidomide (LEN) is commonly used as an effective therapeutic agent for multiple myeloma (MM). However, in some patients, primary resistance to LEN is observed, the mechanisms of which remain poorly understood. In this study, we combined a LEN sensitivity assay with proteomics data from 1...

Full description

Saved in:
Bibliographic Details
Main Authors: Takumi Yamamoto, Arisu Furukawa, Yue Zhou, Nobuaki Kono, Shojiro Kitajima, Hiroto Ohguchi, Yawara Kawano, Shingo Ito, Norie Araki, Sumio Ohtsuki, Takeshi Masuda
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:iScience
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004224026245
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846113140458127360
author Takumi Yamamoto
Arisu Furukawa
Yue Zhou
Nobuaki Kono
Shojiro Kitajima
Hiroto Ohguchi
Yawara Kawano
Shingo Ito
Norie Araki
Sumio Ohtsuki
Takeshi Masuda
author_facet Takumi Yamamoto
Arisu Furukawa
Yue Zhou
Nobuaki Kono
Shojiro Kitajima
Hiroto Ohguchi
Yawara Kawano
Shingo Ito
Norie Araki
Sumio Ohtsuki
Takeshi Masuda
author_sort Takumi Yamamoto
collection DOAJ
description Summary: Lenalidomide (LEN) is commonly used as an effective therapeutic agent for multiple myeloma (MM). However, in some patients, primary resistance to LEN is observed, the mechanisms of which remain poorly understood. In this study, we combined a LEN sensitivity assay with proteomics data from 15 MM cell lines to identify protein expression profiles associated with primary LEN resistance. Our findings revealed that CSN5 expression is lower in LEN-resistant cell lines than in LEN-sensitive lines. Moreover, we established that CSN5 is degraded via the cullin-RING ubiquitin ligase (CRL)-mediated ubiquitin-proteasome pathway through ubiquitination at lysine 194. Our data suggest that reduced CSN5 expression leads to abnormalities in the ubiquitination cycle of CRL4A, resulting in the inhibition of LEN-mediated degradation of IKZF1 and IKZF3. These findings delineate an additional mechanism of LEN resistance in MM cells and may contribute to the development of alternative therapeutic strategies to overcome LEN resistance.
format Article
id doaj-art-591a78604d6e44db8412ba7e9e8612a2
institution Kabale University
issn 2589-0042
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series iScience
spelling doaj-art-591a78604d6e44db8412ba7e9e8612a22024-12-22T05:29:13ZengElsevieriScience2589-00422024-12-012712111399Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cellsTakumi Yamamoto0Arisu Furukawa1Yue Zhou2Nobuaki Kono3Shojiro Kitajima4Hiroto Ohguchi5Yawara Kawano6Shingo Ito7Norie Araki8Sumio Ohtsuki9Takeshi Masuda10Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, JapanDepartment of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, JapanDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, JapanInstitute for Advanced Biosciences, Keio University, Yamagata 997-0017, JapanInstitute for Advanced Biosciences, Keio University, Yamagata 997-0017, JapanDivision of Disease Epigenetics, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto 860-0811, JapanDepartment of Hematology, Rheumatology, and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, JapanDepartment of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan; Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, JapanDepartment of Tumor Genetics and Biology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, JapanDepartment of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan; Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, JapanInstitute for Advanced Biosciences, Keio University, Yamagata 997-0017, Japan; Corresponding authorSummary: Lenalidomide (LEN) is commonly used as an effective therapeutic agent for multiple myeloma (MM). However, in some patients, primary resistance to LEN is observed, the mechanisms of which remain poorly understood. In this study, we combined a LEN sensitivity assay with proteomics data from 15 MM cell lines to identify protein expression profiles associated with primary LEN resistance. Our findings revealed that CSN5 expression is lower in LEN-resistant cell lines than in LEN-sensitive lines. Moreover, we established that CSN5 is degraded via the cullin-RING ubiquitin ligase (CRL)-mediated ubiquitin-proteasome pathway through ubiquitination at lysine 194. Our data suggest that reduced CSN5 expression leads to abnormalities in the ubiquitination cycle of CRL4A, resulting in the inhibition of LEN-mediated degradation of IKZF1 and IKZF3. These findings delineate an additional mechanism of LEN resistance in MM cells and may contribute to the development of alternative therapeutic strategies to overcome LEN resistance.http://www.sciencedirect.com/science/article/pii/S2589004224026245Molecular biologyCell biologyCancerProteomics
spellingShingle Takumi Yamamoto
Arisu Furukawa
Yue Zhou
Nobuaki Kono
Shojiro Kitajima
Hiroto Ohguchi
Yawara Kawano
Shingo Ito
Norie Araki
Sumio Ohtsuki
Takeshi Masuda
Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells
iScience
Molecular biology
Cell biology
Cancer
Proteomics
title Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells
title_full Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells
title_fullStr Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells
title_full_unstemmed Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells
title_short Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells
title_sort increased csn5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells
topic Molecular biology
Cell biology
Cancer
Proteomics
url http://www.sciencedirect.com/science/article/pii/S2589004224026245
work_keys_str_mv AT takumiyamamoto increasedcsn5expressionenhancesthesensitivitytolenalidomideinmultiplemyelomacells
AT arisufurukawa increasedcsn5expressionenhancesthesensitivitytolenalidomideinmultiplemyelomacells
AT yuezhou increasedcsn5expressionenhancesthesensitivitytolenalidomideinmultiplemyelomacells
AT nobuakikono increasedcsn5expressionenhancesthesensitivitytolenalidomideinmultiplemyelomacells
AT shojirokitajima increasedcsn5expressionenhancesthesensitivitytolenalidomideinmultiplemyelomacells
AT hirotoohguchi increasedcsn5expressionenhancesthesensitivitytolenalidomideinmultiplemyelomacells
AT yawarakawano increasedcsn5expressionenhancesthesensitivitytolenalidomideinmultiplemyelomacells
AT shingoito increasedcsn5expressionenhancesthesensitivitytolenalidomideinmultiplemyelomacells
AT noriearaki increasedcsn5expressionenhancesthesensitivitytolenalidomideinmultiplemyelomacells
AT sumioohtsuki increasedcsn5expressionenhancesthesensitivitytolenalidomideinmultiplemyelomacells
AT takeshimasuda increasedcsn5expressionenhancesthesensitivitytolenalidomideinmultiplemyelomacells